Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OGESTREL 0.5/50-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic, via CYP3A4; norgestrel undergoes reduction, conjugation; ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norgestrel: 93-95% to albumin and SHBG; Ethinyl estradiol: 97-98% to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norgestrel: 2.5-3.5 L/kg; Ethinyl estradiol: 2.5-4 L/kg. Indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Norgestrel ~95%; Ethinyl estradiol ~40-60% due to first-pass metabolism.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal disease due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute or chronic hepatic disease; do not use in Child-Pugh class B or C. Use with caution in mild impairment (Child-Pugh A) at minimal effective dose.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (one tablet daily for 21 days).
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause. In elderly patients, evaluate cardiovascular and hepatic status; consider lower estrogen dose if necessary.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders; hepatic neoplasia; elevated blood pressure; gallbladder disease; carbohydrate and lipid metabolism effects; breakthrough bleeding and spotting; use in pregnancy; depression; contact lens intolerance; fluid retention; hereditary angioedema.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast; carcinoma of the endometrium or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; jaundice with prior pill use; hepatic adenoma or carcinoma; age >35 and smoking ≥15 cigarettes/day.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Grapefruit juice may inhibit CYP3A4 metabolism of ethinyl estradiol, potentially increasing estrogen exposure and risk of adverse effects. Avoid large quantities (e.g., >1 quart/day). No other significant food interactions. St. John's Wort may reduce contraceptive efficacy.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: limb defects, cardiac anomalies; second/third trimester: feminization of male fetus, urogenital abnormalities.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk; may reduce milk production and composition. M/P ratio not established. Use not recommended in nursing mothers.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustments as use is contraindicated during pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
This combination oral contraceptive (COC) contains 0.5 mg norgestrel (a progestin) and 50 mcg ethinyl estradiol (a high-estrogen dose). It is a monophasic 21-day regimen. Use for contraception; also FDA-approved for moderate acne vulgaris in women >=15 years. High estrogen dose increases thrombotic risk; avoid in smokers over 35, hypertension, migraine with aura, or history of VTE. Advise consistent intake time (daily, same time). Breakthrough bleeding may occur; rule out pregnancy if missed pills. Antiepileptics (e.g., phenytoin, carbamazepine) and rifampin reduce efficacy.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time for 21 days, then 7 days off; withdrawal bleeding occurs during the 7-day break.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 2 hours of taking it, or have severe diarrhea.,This pill does not protect against HIV or other sexually transmitted infections.,Serious side effects: leg pain (DVT), chest pain (PE), severe headache (stroke), jaundice (liver disease); stop and call doctor immediately.,Do not smoke while taking this pill, especially if over 35; smoking greatly increases risk of blood clots.,Tell your doctor if you are breastfeeding, planning pregnancy, or have any medical conditions (e.g., hypertension, diabetes, migraine).,Grapefruit juice may increase estrogen levels; avoid excessive consumption.,Antibiotics (e.g., rifampin) and certain anticonvulsants can reduce effectiveness.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OGESTREL 0.5/50-21 vs ALYACEN 777, answered by our medical review team.
OGESTREL 0.5/50-21 is a Oral Contraceptive that works by Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OGESTREL 0.5/50-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OGESTREL 0.5/50-21 is: One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OGESTREL 0.5/50-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OGESTREL 0.5/50-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: limb defects, cardiac anomalies; second/third trimester: feminization of male fetus. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.